Cargando…

Omalizumab and Other New Drug Therapies Occupy a Small Space in Asthma Disease Management

Detalles Bibliográficos
Autor principal:	Curtiss, Frederic R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2009
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438079/ https://www.ncbi.nlm.nih.gov/pubmed/19326961 http://dx.doi.org/10.18553/jmcp.2009.15.3.289

Ejemplares similares

Selectivity and Specificity Are the Keys to Cost-Effective Use of Omalizumab for Allergic Asthma
por: Curtiss, Frederic R.
Publicado: (2005)

Chasing Quality - Clinical Practice Guidelines and HEDIS Measures of Asthma and Depression Therapy Management
por: Curtiss, Frederic R.
Publicado: (2006)

Asthma Disease Management-Evidence-Based Medicine Must Be Dynamic
por: Curtiss, Frederic R.
Publicado: (2006)

Omalizumab Has a Place in Therapy for Asthma Disease Management
por: Pesko, Lawrence J.
Publicado: (2009)

Is Omalizumab a Problem-Solving Remedy in Severe Asthma?
por: Kim, Doh Hyung, et al.
Publicado: (2018)

Omalizumab: Clinical Use for the Management of Asthma
por: Thomson, Neil C., et al.
Publicado: (2012)

The Editors Respond: The Diminishing Role of Montelukast in Asthma Therapy
por: Crownover, Brian K., et al.
Publicado: (2006)

Update on optimal use of omalizumab in management of asthma
por: Pelaia, Girolamo, et al.
Publicado: (2011)

A review of omalizumab for the management of severe asthma
por: Lin, Ching-Hsiung, et al.
Publicado: (2016)

Prior Authorization to Manage Drug Utilization and Costs
por: Curtiss, Frederic R.
Publicado: (2003)

More Evolution of the Evidence in Asthma Disease Management-SMART Versus GOAL Clinical Trials Debate the Cost-Benefit of LABA While the Value of Leukotriene Modifiers, Particularly Montelukast, Is Uncertain
por: Curtiss, Frederic R.
Publicado: (2006)

Severe asthma and the omalizumab option
por: Miller, Christopher WT, et al.
Publicado: (2008)

Omalizumab treatment in brittle asthma
por: Skiepko, Roman, et al.
Publicado: (2014)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

Diabetes Drug Therapy -- First Do No Harm
por: Curtiss, Frederic R., et al.
Publicado: (2008)

Pharmacy Benefit Spending Poised to Increase for Antithrombotic Drug Therapy--Prasugrel Versus Clopidogrel
por: Curtiss, Frederic R.
Publicado: (2009)

Hypertension, Prescription Drug Copayments, and Drug Therapy Adherence
por: Curtiss, Frederic R.
Publicado: (2003)

Omalizumab for severe allergic asthma: a life changing drug?
por: Mesonjesi, Eris, et al.
Publicado: (2015)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

The Relative Value of Disease Management Programs Versus Drug Manufacturer Rebates
por: Curtiss, Frederic R.
Publicado: (2003)

Omalizumab in the management of patients with allergic (IgE-mediated) asthma
por: Sandström, Thomas
Publicado: (2009)

Omalizumab as add-on therapy in patients with asthma and allergic bronchopulmonary aspergillosis
por: da Cunha, Fernanda Sales, et al.
Publicado: (2018)

Omalizumab as add‐on therapy in a patient with severe asthma and OSA
por: Scioscia, Giulia, et al.
Publicado: (2020)

Omalizumab as a new therapeutic approach for children with severe asthma
por: Jerzyńska, Joanna, et al.
Publicado: (2014)

Disease Management Oppurtunities for IBS - Placebo Versus Active Therapy
por: Curtiss, Frederic R.
Publicado: (2004)

Poster 1012: Safety and efficacy of omalizumab in 10 children with asthma and other allergic comorbidities
por: Aguiar, Rita, et al.
Publicado: (2014)

Managed Care and Health Care Reform: Everything Old Is New Again
por: Fairman, Kathleen A., et al.
Publicado: (2009)

False-Positive Versus True-Positive Drug-Drug Interactions With Warfarin
por: Curtiss, Frederic R.
Publicado: (2006)

Depicting a cellular space occupied by condensates
por: Liu, Daniel, et al.
Publicado: (2023)

Methods to Attain Optimal Outcomes With Lipid-Lowering Drug Therapy
por: Curtiss, Frederic R.
Publicado: (2004)

Contractual Arrangements Between HMOs and Medical Groups to Manage Drug Costs
por: Curtiss, Frederic R.
Publicado: (2003)

Medication Therapy Management Programs - Will Patient Need be Satisfied
por: Curtiss, Frederic R.
Publicado: (2005)

Dermatomyositis associated with omalizumab therapy for severe asthma: a case report
por: Jeimy, Samira, et al.
Publicado: (2019)

COX-2 Inhibitors: Little or No GI Protection, Increased Risk of Cardiovascular Events, High Cost, and Other Class-less Effects
por: Curtiss, Frederic R.
Publicado: (2005)

Drug Formulary Decisions - Evaluating the Risks and Benefits of Hormone Replacement Therapy
por: Curtiss, Frederic R.
Publicado: (2004)

279 Near-Fatal Asthma Treated with Omalizumab
por: Contreras Contreras, Elvia Angelica, et al.
Publicado: (2012)

Anaesthetic management of a pregnant patient with intracranial space occupying lesion for craniotomy
por: Marulasiddappa, Vinay, et al.
Publicado: (2014)

Preventing Medication Errors and Adverse Drug Events
por: Curtiss, Frederic R.
Publicado: (2003)

Burden of Prescription Drug Costs in the United States
por: Curtiss, Frederic R.
Publicado: (2003)

Pharmacoeconomic Modeling of Drug Therapies for Multiple Sclerosis - Are We Building Houses on Sand?
por: Curtiss, Frederic R.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_qp867n3juklsqp4r4gtj0q29lq